Lipid Metabolism Practice Questions

Q: Which enzyme regulates the synthesis of ketone bodies?

Beta-hydroxy-beta-methylglutaryl CoA synthase. **Explanation:** **1. Why Option A is Correct:** The synthesis of ketone bodies (ketogenesis) occurs primarily in the mitochondria of liver cells. The **rate-limiting enzyme** for this pathway is **HMG-CoA synthase (mitochondrial isoform)**. This enzyme catalyzes the condensation of Acetoacetyl-CoA with a third molecule of Acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). Because it is the slowest step in the pathway, its activity determines the overall rate of ketone body production. **2. Why Other Options are Incorrect:** * **Option B (Beta-hydroxybutyrate):** This is not an enzyme; it is one of the three primary ketone bodies (along with acetoacetate and acetone). It serves as a major energy source for peripheral tissues during starvation. * **Option C (Acetyl CoA):** This is the **substrate** (starting material) for ketogenesis, not the regulatory enzyme. While high levels of Acetyl-CoA (derived from fatty acid oxidation) drive the pathway, the regulation is governed by the enzyme HMG-CoA synthase. **3. NEET-PG High-Yield Clinical Pearls:** * **Location Specificity:** HMG-CoA synthase has two isoforms. The **mitochondrial** enzyme is for **ketogenesis**, while the **cytosolic** enzyme is for **cholesterol synthesis**. * **HMG-CoA Reductase:** Do not confuse the two; HMG-CoA *Reductase* is the rate-limiting enzyme for cholesterol synthesis and is the target of Statin drugs. * **Ketolysis:** The liver produces ketone bodies but **cannot utilize them** because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Stimulus:** Ketogenesis is stimulated by a high Glucagon:Insulin ratio, typically seen in prolonged fasting or uncontrolled Diabetes Mellitus (leading to DKA).

Q: Which is the most essential fatty acid?

Linoleic acid. **Explanation:** The concept of "essentiality" in fatty acids refers to the body's inability to synthesize them due to the lack of enzymes (**desaturases**) capable of introducing double bonds beyond the $\Delta^9$ position. **1. Why Linoleic Acid is the Correct Answer:** Linoleic acid (18:2; $\omega$-6) is considered the **most essential** fatty acid because it cannot be synthesized by the human body and must be obtained from the diet. It serves as the primary precursor for the synthesis of Arachidonic acid. If Linoleic acid is present in sufficient quantities, the body can produce other $\omega$-6 derivatives. **2. Analysis of Incorrect Options:** * **Linolenic acid (18:3; $\omega$-3):** While also an essential fatty acid, it is generally considered secondary to Linoleic acid in the context of standard medical examinations unless specifically discussing $\omega$-3 pathways. * **Arachidonic acid (20:4; $\omega$-6):** It is a **semi-essential** fatty acid. It becomes essential only if its precursor, Linoleic acid, is deficient in the diet. * **Palmitic acid (16:0):** This is a saturated fatty acid and is the first fatty acid produced by the fatty acid synthase complex in the body; hence, it is non-essential. **High-Yield Clinical Pearls for NEET-PG:** * **True Essential Fatty Acids:** Linoleic acid ($\omega$-6) and $\alpha$-Linolenic acid ($\omega$-3). * **Deficiency Manifestations:** Phrynoderma (Toad skin) characterized by follicular hyperkeratosis, poor wound healing, and alopecia. * **Eicosanoid Precursor:** Arachidonic acid is the immediate precursor for Prostaglandins, Thromboxanes, and Leukotrienes. * **Key Enzyme:** Humans lack $\Delta^{12}$ and $\Delta^{15}$ desaturases.

Q: What is the end product of cytosolic fatty acid synthetase in humans?

Palmitic acid. **Explanation:** The correct answer is **Palmitic acid (D)**. In humans, de novo fatty acid synthesis occurs primarily in the **cytosol** of liver and mammary gland cells. The process is catalyzed by the **Fatty Acid Synthase (FAS) complex**, a multi-enzyme system. The synthesis begins with Acetyl-CoA and Malonyl-CoA, undergoing a repeating four-step cycle (condensation, reduction, dehydration, and reduction). This cycle repeats until a **16-carbon saturated fatty acid chain** is formed. At this point, the enzyme **thioesterase** releases the final product, which is **Palmitic acid (C16:0)**. **Analysis of Incorrect Options:** * **Oleic acid (A):** This is a C18 monounsaturated fatty acid. It is produced by the elongation and desaturation of palmitic acid in the endoplasmic reticulum, not directly by the cytosolic FAS complex. * **Arachidonic acid (B):** This is a C20 polyunsaturated fatty acid (omega-6). It is synthesized from linoleic acid and is a precursor for eicosanoids (prostaglandins/leukotrienes). * **Linoleic acid (C):** This is an **essential fatty acid** (C18:2). Humans lack the enzymes (desaturases) to introduce double bonds beyond carbon 9; therefore, it cannot be synthesized by the body and must be obtained from the diet. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** Acetyl-CoA Carboxylase (ACC), which requires **Biotin** as a cofactor. * **Reductant:** **NADPH** is the essential electron donor, primarily supplied by the Hexose Monophosphate (HMP) Shunt. * **Transport:** Acetyl-CoA enters the cytosol from the mitochondria via the **Citrate Shuttle** ("Citrate is for Synthesis"). * **Inhibitor:** Palmitoyl-CoA (the end product) provides feedback inhibition to ACC.

Q: Which lipoprotein carries the maximum amount of cholesterol?

Low-Density Lipoprotein (LDL). ### Explanation The correct answer is **Low-Density Lipoprotein (LDL)**. **1. Why LDL is the Correct Answer:** Lipoproteins are classified based on their density and composition. LDL is the primary carrier of cholesterol in the blood, containing approximately **50% cholesterol** (mostly as cholesterol esters). It is formed from the metabolism of VLDL via IDL. Its physiological role is to transport cholesterol from the liver to peripheral tissues. Because it has the highest percentage of cholesterol among all lipoproteins, it is often referred to as "Bad Cholesterol." **2. Why the Other Options are Incorrect:** * **VLDL (Very Low-Density Lipoprotein):** Its primary cargo is **endogenous triglycerides** (approx. 55-65%). It contains only about 10-15% cholesterol. * **HDL (High-Density Lipoprotein):** While it is rich in protein (approx. 50%), its cholesterol content is roughly 20-30%. Its role is "Reverse Cholesterol Transport" (carrying cholesterol from tissues back to the liver). * **Chylomicrons:** These are the largest and least dense lipoproteins. They are primarily composed of **exogenous (dietary) triglycerides** (85-90%) and contain very little cholesterol (approx. 3-5%). **3. High-Yield Clinical Pearls for NEET-PG:** * **Apolipoprotein Marker:** LDL is characterized by **Apo B-100**, which acts as a ligand for the LDL receptor. * **Friedewald Equation:** LDL-C = [Total Cholesterol] – [HDL-C] – [TG/5]. (Note: This is invalid if TG > 400 mg/dL). * **Rate-Limiting Enzyme:** HMG-CoA Reductase is the key enzyme in cholesterol synthesis, targeted by Statins to lower LDL levels. * **Density vs. Size:** As density increases (HDL > LDL > VLDL > Chylomicrons), the size of the particle decreases.

Q: Which of the following is a primary bile acid synthesized in the liver?

Cholic acid. ### Explanation **1. Why Cholic Acid is Correct:** Bile acids are synthesized in the liver from **cholesterol**. This process is categorized into two stages: * **Primary Bile Acids:** These are synthesized directly in the hepatocytes. The two primary bile acids are **Cholic acid** (a trihydroxy acid) and **Chenodeoxycholic acid** (a dihydroxy acid). * The rate-limiting step in this synthesis is catalyzed by the enzyme **7-alpha-hydroxylase**, which is inhibited by bile acids (feedback inhibition). **2. Why the Other Options are Incorrect:** * **Deoxycholic acid (Option C) and Lithocholic acid (Option A):** These are **Secondary Bile Acids**. They are not synthesized by the liver. Instead, they are formed in the intestine through the action of bacterial enzymes (specifically 7-alpha-dehydroxylase) on primary bile acids. * Cholic acid is converted to **Deoxycholic acid**. * Chenodeoxycholic acid is converted to **Lithocholic acid**. * **Option D:** Incorrect because only Cholic acid is primary; the others are secondary metabolites. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Conjugation:** Before secretion into bile, primary bile acids are conjugated with **Glycine** or **Taurine** (forming Glycocholic or Taurocholic acid) to increase their solubility at physiological pH. * **Enterohepatic Circulation:** About 95% of bile acids are reabsorbed in the **terminal ileum** and returned to the liver via the portal vein. * **Steatorrhea:** Malabsorption of bile acids (e.g., in Crohn’s disease affecting the terminal ileum) leads to fat malabsorption and foul-smelling, fatty stools. * **Cholestyramine:** A bile acid sequestrant used to treat hypercholesterolemia by preventing the reabsorption of bile acids, forcing the liver to use more cholesterol to synthesize new ones.

Q: Tangier disease is characterized by which of the following lipid abnormalities?

Extremely low circulating level of plasma cholesterol. **Explanation:** **Tangier Disease** is an autosomal recessive disorder caused by a mutation in the **ABCA1 gene** (ATP-binding cassette transporter A1). This transporter is responsible for the efflux of cholesterol and phospholipids from peripheral cells to lipid-poor **Apolipoprotein A-I (Apo A-I)** to form nascent HDL. 1. **Why Option A is Correct:** In Tangier disease, the defect in ABCA1 prevents the formation of HDL. Consequently, Apo A-I is rapidly cleared by the kidneys. This leads to a **near-total absence of HDL** in the plasma. Since HDL is a major carrier of cholesterol, its absence results in **extremely low circulating levels of plasma cholesterol** (typically <30 mg/dL). 2. **Why Incorrect Options are Wrong:** * **Option B:** In Tangier disease, HDL is virtually absent, not high. LDL levels are also typically reduced (hypocholesterolemia), not just LDL alone. * **Options C & D:** Triglyceride levels in Tangier disease are usually **normal or mildly elevated** (hypertriglyceridemia), but the hallmark of the disease is the profound drop in cholesterol and HDL, not a specific extreme fluctuation in triglycerides. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Sign:** Large, **orange-colored tonsils** (due to accumulation of cholesteryl esters in reticuloendothelial cells). * **Clinical Features:** Hepatosplenomegaly, lymphadenopathy, and peripheral neuropathy. * **Biochemical Hallmark:** Absence of HDL and very low Apo A-I levels. * **Histology:** Presence of "foam cells" in tissues like the bone marrow and rectal mucosa.

Q: What is the primary role of bile salts?

Emulsification of lipids. **Explanation:** The primary role of bile salts is the **emulsification of dietary lipids**. Lipids are hydrophobic and tend to aggregate into large globules in the aqueous environment of the small intestine. Bile salts (derivatives of cholesterol like cholate and chenodeoxycholate) are **amphipathic** molecules, meaning they possess both hydrophilic and hydrophobic faces. They coat lipid droplets, reducing surface tension and breaking them down into smaller particles. This increases the surface area available for **pancreatic lipase** to act, which is essential for efficient lipid digestion and subsequent micelle formation. **Analysis of Incorrect Options:** * **A. Vitamin B12 absorption:** This requires **Intrinsic Factor**, secreted by the parietal cells of the stomach, and occurs in the terminal ileum. Bile salts are not directly involved. * **B. Formation of lipid bilayer:** This is the structural role of **phospholipids** (like phosphatidylcholine) and cholesterol within cell membranes, not the functional role of bile salts in digestion. * **C. Fatty acid degradation:** This refers to **Beta-oxidation**, which occurs intracellularly within the mitochondria. Bile salts function extracellularly in the intestinal lumen. **NEET-PG High-Yield Pearls:** * **Rate-limiting step:** Bile acid synthesis is regulated by the enzyme **7-alpha-hydroxylase** (inhibited by bile acids). * **Enterohepatic Circulation:** Approximately 95% of bile salts are reabsorbed in the **terminal ileum** and returned to the liver. * **Clinical Correlation:** Malabsorption of bile salts (e.g., in Crohn’s disease affecting the ileum) leads to **steatorrhea** and deficiency of fat-soluble vitamins (A, D, E, K). * **Composition:** Bile salts are bile acids conjugated with **glycine or taurine**, which lowers their pKa and makes them better emulsifiers at intestinal pH.

Q: What is the first step in the synthesis of eicosanoids?

Activation of hydrolase. **Explanation:** The synthesis of eicosanoids (prostaglandins, leukotrienes, and thromboxanes) begins with the release of the precursor fatty acid, typically **arachidonic acid**, from the cell membrane. **1. Why "Activation of hydrolase" is correct:** Arachidonic acid is not found free in the cytosol; it is esterified in membrane phospholipids. The **rate-limiting and first step** in eicosanoid synthesis is the liberation of arachidonic acid by the enzyme **Phospholipase A2 (PLA2)**. Since Phospholipase A2 is a type of **hydrolase** (it uses water to cleave the ester bond at the sn-2 position of phospholipids), its activation is the mandatory initial step before any downstream processing can occur. **2. Why the other options are incorrect:** * **Option A (Lipoxygenase):** This enzyme acts on free arachidonic acid to produce leukotrienes. It is part of the "linear pathway" but occurs only *after* the hydrolase has released the substrate. * **Option B (PGH2 synthetase):** Also known as Cyclooxygenase (COX), this enzyme converts free arachidonic acid into prostaglandins and thromboxanes (the "cyclic pathway"). Like lipoxygenase, it cannot act until the hydrolase step is complete. **High-Yield Clinical Pearls for NEET-PG:** * **Glucocorticoids** inhibit eicosanoid synthesis by inducing **Lipocortin (Annexin A1)**, which inhibits Phospholipase A2. * **Arachidonic acid** is an omega-6 fatty acid (20:4, Δ5,8,11,14) derived from the essential fatty acid **linoleic acid**. * **Rate-limiting step:** Release of arachidonic acid by PLA2. * **Key Inhibitors:** NSAIDs and Aspirin inhibit the COX pathway, but not the PLA2 or lipoxygenase pathways.

Q: Krabbe's disease is caused by a defect of which enzyme?

Galactosyl ceramidase. **Explanation:** **Krabbe’s disease** (also known as Globoid Cell Leukodystrophy) is an autosomal recessive lysosomal storage disorder. It is caused by a deficiency of the enzyme **Galactosyl ceramidase** (also called galactocerebrosidase). Under normal conditions, this enzyme breaks down galactocerebroside into galactose and ceramide. When deficient, galactocerebroside and its toxic derivative, **psychosine**, accumulate. Psychosine is particularly toxic to oligodendrocytes, leading to widespread demyelination in the central and peripheral nervous systems. **Analysis of Options:** * **Option A: Ceramidase** – Deficiency leads to **Farber disease**, characterized by painful joint swelling, hoarseness (laryngeal involvement), and subcutaneous nodules. * **Option B: Beta-galactosidase** – Deficiency leads to **GM1 Gangliosidosis**, which presents with hepatosplenomegaly and skeletal deformities (dysostosis multiplex). * **Option C: Alpha-galactosidase** – Deficiency leads to **Fabry disease**, an X-linked disorder characterized by angiokeratomas, peripheral neuropathy (burning pain), and renal failure. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Feature:** Presence of **Globoid cells** (multinucleated macrophages) in the brain white matter. * **Clinical Presentation:** Irritability, severe developmental delay, limb rigidity, and optic atrophy in early infancy. * **Inheritance:** Autosomal Recessive. * **Mnemonic:** "The **Krab** is **Galactic**" (Krabbe = Galactosyl ceramidase).

Question 1

Which enzyme regulates the synthesis of ketone bodies?

Accepted Answer

Beta-hydroxy-beta-methylglutaryl CoA synthase

Answer

Beta-hydroxybutyrate

Answer

Acetyl CoA

Answer

None of the above

Question 2

Which is the most essential fatty acid?

Accepted Answer

Linoleic acid

Answer

Linolenic acid

Answer

Arachidonic acid

Answer

Palmitic acid

Question 3

In liver cells, triglycerides are primarily formed in which organelle?

Accepted Answer

Smooth endoplasmic reticulum

Answer

Rough endoplasmic reticulum

Answer

Golgi apparatus

Answer

Ribosomes

Question 4

What is the end product of cytosolic fatty acid synthetase in humans?

Accepted Answer

Palmitic acid

Answer

Oleic acid

Answer

Arachidonic acid

Answer

Linoleic acid

Question 5

Which lipoprotein carries the maximum amount of cholesterol?

Accepted Answer

Low-Density Lipoprotein (LDL)

Answer

Very Low-Density Lipoprotein (VLDL)

Answer

High-Density Lipoprotein (HDL)

Answer

Chylomicrons

Question 6

Which of the following is a primary bile acid synthesized in the liver?

Accepted Answer

Cholic acid

Answer

Lithocholic acid

Answer

Deoxycholic acid

Answer

All of the above

Question 7

Tangier disease is characterized by which of the following lipid abnormalities?

Accepted Answer

Extremely low circulating level of plasma cholesterol

Answer

Low level of LDL but high HDL level

Answer

Extremely low level of triglycerides

Answer

Very high level of triglycerides

Question 8

What is the primary role of bile salts?

Accepted Answer

Emulsification of lipids

Answer

Vitamin B12 absorption

Answer

Formation of lipid bilayer

Answer

Fatty acid degradation

Question 9

What is the first step in the synthesis of eicosanoids?

Accepted Answer

Activation of hydrolase

Answer

Activation of lipoxygenase

Answer

Activation of PGH2 synthetase

Answer

None of the above

Question 10

Krabbe's disease is caused by a defect of which enzyme?

Accepted Answer

Galactosyl ceramidase

Answer

Ceramidase

Answer

Beta-galactosidase

Answer

Alpha-galactosidase

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?